HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A lipophilic nitric oxide donor and a lipophilic antioxidant compound protect rat heart against ischemia-reperfusion injury if given as hybrid molecule but not as a mixture.

Abstract
Low concentrations of a hydrophilic nitric oxide donor (NOD) are reported to reduce myocardial reperfusion injury only when combined with a lipophilic antioxidant (AOX) to form a hybrid molecule (HYB). Here we tested whether liposoluble NOD requires to be combined with AOX to be protective. Isolated rat hearts underwent 30 minutes of ischemia and 120 minutes of reperfusion. To induce postconditioning, 1 μM solutions of the following liposoluble compounds were given during the first 20 minutes of reperfusion: NOD with weak (w-NOD) or strong NO-releasing potency (s-NOD); weak HYB built up with w-NOD and a per se ineffective AOX lead; strong HYB built up with s-NOD and the same AOX; mixtures of w-NOD plus AOX or s-NOD plus AOX. A significant reduction of infarct size with improved recovery of cardiac function was obtained only with weak HYB. We suggest that w-NOD requires the synergy with a per se ineffective AOX to protect. The synergy is possible only if the 2 moieties enter the cell simultaneously as a hybrid, but not as a mixture. It seems that strong HYB was ineffective because an excessive intracellular NO release produces a large amount of reactive species, as shown from the increased nitrotyrosine production.
AuthorsRaffaella Rastaldo, Rastaldo Raffaella, Sandra Cappello, Cappello Sandra, Antonella Di Stilo, Di Stilo Antonella, Anna Folino, Folino Anna, Gianni Losano, Losano Gianni, Pasquale Pagliaro, Pagliaro Pasquale
JournalJournal of cardiovascular pharmacology (J Cardiovasc Pharmacol) Vol. 59 Issue 3 Pg. 241-8 (Mar 2012) ISSN: 1533-4023 [Electronic] United States
PMID22030894 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antioxidants
  • Cardiotonic Agents
  • Nitric Oxide Donors
  • Nitric Oxide
  • 3-nitrotyrosine
  • Tyrosine
Topics
  • Animals
  • Antioxidants (administration & dosage, chemistry, pharmacology)
  • Cardiotonic Agents (administration & dosage, chemistry, pharmacology)
  • Drug Synergism
  • Ischemic Postconditioning (methods)
  • Male
  • Myocardial Infarction (physiopathology, prevention & control)
  • Myocardial Reperfusion Injury (physiopathology, prevention & control)
  • Nitric Oxide (metabolism)
  • Nitric Oxide Donors (administration & dosage, chemistry, pharmacology)
  • Rats
  • Rats, Wistar
  • Tyrosine (analogs & derivatives, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: